The basic helix-loop-helix (bHLH) family of proteins (48) includes many that are pivotal in cell type determination, such as the MyoD group (including MyoD, myogenin, myf-5, and MRF4) for skeletal myogenesis (10, 20, 55, 73, 75) . The bHLH proteins form homo-or heterodimers through the HLH domain and bind to DNA through the adjacent basic region (BR) (16, 72) . They bind as dimers to DNA sites that generally share the consensus CANNTG (the E box) (8, 49) , with each BR occupying half of the site (8, 19, 21, 44) .
MyoD family members form homodimers relatively inefficiently (67) and instead appear to activate transcription of muscle-specific genes as heterodimers with the widely expressed E proteins (including E2A [E12 and E47], E2-2, and HEB [3] ) (41) . E proteins also form heterodimers with other tissue-specific bHLH proteins (49) , to regulate still different sets of genes in various tissues such as erythrocytes (1) , pancreas (51) , and neurons (36) , and they form homodimers which are essential for B-cell differentiation (4, 18, 39) . The ability of these different protein complexes to regulate different sets of genes appears paradoxical, because their DNA binding specificities are often surprisingly overlapping. For example, certain sites that can be bound well by either MyoD-E or E-E complexes in vitro (8, 49) can be activated by only one or the other of these complexes in the cell (25, 77) . It therefore appears either that other protein factors are involved in determining transcriptional specificity or that subtle differences in DNA binding specificity of the bHLH proteins must be biologically significant. These two mechanisms may not be mutually exclusive. Evidence suggests that MyoD may require a positive cofactor to activate transcription of appropriate genes (9, 16, 17, 47, 76) and that it can be prevented from acting at inappropriate sites by repressors that recognize bases overlapping the E box (25, 77) . Remarkably, these proposed cofactor and repressor functions both appear to depend on the presence of particular MyoD BR residues, mutations of which may allow DNA binding but not transcriptional activity. X-ray crystallographic studies indicate that in the bound complex these MyoD residues are in intimate proximity to the DNA and that the MyoD BR assumes a binding conformation different from that of the E47 protein (19, 44) , suggesting that this conformation may in turn constitute an important aspect of interactions between MyoD (or other bHLH proteins) and coactivator or repressor functions at the promoter.
In light of these observations, it is critical to study systematically the DNA sequence requirements for transcriptional activation by bHLH proteins. Preferred binding sites for MyoD and E proteins have been identified by random-sequence selection in vitro (8, 67, 79) , but such assays cannot predict the ability of these proteins to support transcriptional activation. To this end, we have developed the first system that allows proteins to select functional DNA targets from random sequences in mammalian cells. In this new method, dubbed the selection of in vivo target elements (SITE) technique (Fig.  1A) , oligonucleotides with random sequences at positions of interest were embedded in a muscle-specific promoter cassette, in this case the human cardiac ␣-actin (HCA) enhancer/promoter cassette, located upstream of a ␤-galactosidase (␤-Gal) reporter gene. The resulting plasmid library was cotransfected with a MyoD expression vector into murine NIH 3T3 fibroblasts, cells that expressed ␤-Gal were then selected by fluorescence-activated cell sorting (FACS), and finally plasmid DNA was extracted from selected cells and amplified in Escherichia coli to allow this selection procedure to be repeated. Three such selection rounds yielded sequences through which MyoD can activate transcription in vivo. These sequences overlap with but are generally distinct from optimal MyoD or MyoD-E binding sites identified in vitro (8, 79) . Instead, the selected sites are similar to various functional E boxes present in native muscle-specific promoters. Remarkably, the active sequences selected from the HCA promoter context do not necessarily activate transcription in the context of another muscle-specific promoter, such as the muscle creatine kinase (MCK) promoter. These findings indicate, surprisingly, that the optimal binding sites are not always capable of activating transcription and suggest that binding per se is not sufficient for activation, which may thus be very sensitive to promoter context and/or binding conformation.
MATERIALS AND METHODS
Plasmid constructions. The reporter plasmid pool pNNN-␤-gal (Fig. 1A) was constructed by ligating HCA promoter region Ϫ89 to ϩ68 (46) containing each random nucleotide cassette (Fig. 1B) , the lacZ reporter gene from the pNASS␤ vector (Clontech), and a fragment from the pBluescript II KS (ϩ) vector (Stratagene) that contained the ampicillin resistance gene and the ColE1 bacterial replication origin. Two E boxes (PvuII sites) in the plasmid backbone were deleted to allow unambiguous analysis. The MyoD expression vector used for SITE experiments, pMyoD-Kan (Fig. 1A) , was derived from the pEMSV-MyoD expression vector (16) by inserting the kanamycin resistance gene at the ScaI site of the ampicillin resistance gene, which inactivates the latter selection marker.
In plasmid 115MCK-␤-gal, the MCK enhancer region (Ϫ1207 to Ϫ1093) and promoter region (Ϫ82 to ϩ7) were used to drive the lacZ reporter gene in the same plasmid backbone as in pNNN-␤-gal. The various E-box substitutions into the MCK context (Fig. 4) were created by mutagenesis using PCR (31) and confirmed by DNA sequence analysis.
Cell culture and transfection. NIH 3T3 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% bovine calf serum (Gibco). Cells were cotransfected with 7.5 g of ␤-Gal reporter plasmid and 7.5 g of MyoD expression vector per 10-cm-diameter plate by calcium phosphate coprecipitation (12) . Seventeen to 21 h posttransfection, the cells were switched to differentiation medium (Dulbecco's modified Eagle's medium containing 2% horse serum [Gibco] plus transferrin [Sigma; 10 g/ml] and insulin [Sigma; 10 g/ml]) for 2 days before they were harvested for FACS.
FACS selection of ␤-Gal ؉ cells. Cells were washed three times with 1ϫ phosphate-buffered saline (PBS), detached and dissociated in 5 mM EDTA in PBS, and passed through a 23-gauge needle to further dissociate doublets or bigger clumps. (EDTA was used instead of trypsin because plasma membrane damage caused by trypsin would increase leakage during and after the hypotonic shock.) The cells were resuspended in 50 l of 1ϫ PBS at 1 ϫ 10 7 to 5 ϫ 10 7 cells per ml, transferred to Falcon 2058 tubes, and warmed to 37ЊC. Flow cytometry analysis of ␤-Gal activity of the cells was performed as described previously (22, 53) . Briefly, 50 l of 2 mM fluorescein di-␤-D-galactoside (FDG; Molecular Probes) in H 2 O was added to the cells, and the mixture was incubated at 37ЊC for 1 min. At the end of the incubation, 10 volumes (1 ml) of ice-cold 1ϫ PBS was immediately added, and the reaction mixture was placed on ice for 20 to 60 min. The reaction was terminated by addition of 2 mM phenylethyl-␤-D-thiogalactoside (Molecular Probes). Prior to sorting, propidium iodide (Sigma) was added (5 g/ml). Cells were analyzed and sorted at 4ЊC on a FACS machine (Vantage; Becton Dickinson). Fluorescein isothiocyanate (FITC)-positive cells (in which FDG had been converted to fluorescein) were collected into a 35-mm-diameter Falcon dish coated with 1% SeaPlaque agarose in 1ϫ PBS.
Recovery of plasmids from FACS-selected cells. Plasmids in the sorted cells were extracted by the Hirt protocol (32). Electroporation of highly competent E. coli cells was used for efficient recovery of selected plasmids (29) . Since the lacZ reporter plasmid and the MyoD expression vector were constructed to carry different bacterial selection markers (Fig. 1A) , the reporter plasmids can be selectively amplified in E. coli. The bacterial transformants were pooled, and plasmids were extracted from them (Maxiprep; Qiagen). In the final round of the FIG. 1. Selection scheme. (A) An oligonucleotide was synthesized with random sequences (designated N) at positions of interest in the protein-binding site. A double-stranded cassette was generated by extension over a complementary segment and cut with appropriate restriction enzymes at both ends. The cassette was then ligated unidirectionally into a ␤-Gal reporter plasmid such that transcription of the ␤-Gal gene is under the control of the randomized enhancer/promoter cassette. The ligation mixture was electroporated into E. coli cells, the transformants were plated on LB-agarose-ampicillin plates and allowed to form colonies, which were then pooled, and the plasmids were extracted. (The size of the plasmid library was made larger than 4.6 ϫ 4 n , n being the number of nucleotides made random, to ensure a probability of no less than 99% to encompass the complexity of the library 4 n [59] .) The plasmid pool was cotransfected with a MyoD expression plasmid into 3T3 cells, and ␤-Gal ϩ cells were collected by using a fluorescence-activated cell sorter, the stringency of selection being controlled by fluorescence gating. The plasmids in the collected cells were retrieved by the Hirt protocol, amplified by transformation back into E. coli cells, and used for the next round of selection. After the desired number of rounds of selection, the active enhancer sequences were determined by DNA sequencing and confirmed by a transfection test. (B) Core sequences of the random cassettes 4N and 222N. The 18-bp core sequences of 4N and 222N are based on the MyoD binding site of the HCA promoter (46) . The consensus CA--TG motif is indicated by dots. 222N selection, individual bacterial transformants were picked arbitrarily and plasmids were extracted (Miniprep; Promega).
Sequencing of recovered plasmids. DNA sequencing was done by the dideoxy method (61), using Sequenase (U.S. Biochemical).
␤-Gal assays. ␤-Gal activities of transfected cells were monitored by either 5-bromo-4-chloro-3-indolylphosphate-␤-D-galactopyranoside (X-Gal) staining of fixed cells (60) or o-nitrophenyl-␤-D-galactopyranoside (ONPG) and GalactonPlus (Tropix) hydrolysis by cell lysates, in accordance with standard protocols (59) or the manufacturer's instructions, respectively.
RESULTS AND DISCUSSION
The CANNTG motif is selected by MyoD to activate transcription. A transient-transfection approach was used both to generate MyoD-expressing cells and to select MyoD-responsive sequences. This strategy was chosen because stable expression of MyoD inhibits the cell cycle (15, 27, 28, 66) and because myoblast cells that constitutively express MyoD may fuse, thus complicating selection of individual cells. The selection templates (Fig. 1B) were designed on the basis of the HCA promoter (46) , which is specific to skeletal and cardiac muscle and contains a single E box that is required for MyoD-dependent HCA promoter activity in skeletal muscle (62, 65) . To test the feasibility and fidelity of the SITE approach, we first used the 4N promoter template (Fig. 1B) , in which the CA and TG positions of the E box are random. When NIH 3T3 cells were cotransfected with the 4N pool and a MyoD expression vector, ␤-Gal activity was close to the basal level (Fig. 2C) , suggesting that only a very small portion (if any) of the random-sequence combinations were activated by MyoD. In contrast, after two rounds of selection, the pool ␤-Gal activity was dramatically increased (Fig. 2D) , and the DNA sequence of the recovered plasmids revealed selection for the CA and TG dinucleotides (compare Fig. 2B with Fig. 2A ), thus confirming both their importance and the validity of the selection system. DNA sequence requirement for MyoD transactivation through the CANNTG motif. To identify E boxes through which MyoD can activate transcription, we used the 222N template (Fig. 1B) , in which base pairs of the HCA promoter internal to and flanking the CANNTG consensus are of random sequence. In preliminary studies, we determined by quantitative ␤-Gal assay (59) that the wild-type HCA sequence can generate signals at least 50-fold over the level in nontransfected cells or cells transfected with a mutant construct. Consequently, we set the FACS gates for FITC-positive cells at levels well above basal levels in order to allow selection of cells with only the highest levels of ␤-Gal activity, which probably contain multiple copies of the most active sequences. In the first round, the cells that were cotransfected with the 222N population and MyoD turned the solutions slightly yellow (as a result of FITC leakage) during the loading of FDG, suggesting that the 222N pool contained a considerable portion of active sequence. However, this activity was clearly much lower than that observed for the wild-type sequence. Three rounds of increasingly stringent FACS selection yielded a sequence pool with activity that was significantly higher than that of the starting population, as is apparent from the appearance of a new peak in the FACS spectrum (Fig. 3A) . This dramatic improvement in pool activity is also indicated by much more leaking of visible FITC from the cells during the FDG loading procedure in the final round.
When individual plasmids recovered from this pool were assayed for transcriptional activation by cotransfected MyoD, most (15 of 17) were active, some (4 of 17) even more so than the wild-type HCA promoter. Of this last most active group, two (sequences 5 and 15) were represented multiple times (Fig. 3B) . None of these selected sequences were active without cotransfection of the MyoD expression vector or could be activated by expression of the E proteins alone. Although a background of inactive plasmids (2 of 26) was still present in the selected pool, these results confirm that the selection procedure enriched significantly for MyoD-responsive sequences (Fig. 3B) .
Differences between in vivo activation and in vitro DNA binding. Only a subset of the possible E-box CANNTG hexamer core site motifs were represented among the selected molecules that were responsive to MyoD, none of which contained the CACGTG hexamers to which MyoD or MyoD-E complexes are known not to bind (7) . Of the 10 sequences that were at least half as active as the wild-type HCA promoter, one contained the wild-type CAACTG hexamer core sequence, four contained a CAAGTG hexamer, and five contained a CAGGTG sequence. Previously, binding-site selections performed in vitro demonstrated that MyoD homodimers and MyoD-E47 heterodimers prefer sites that contain the CAGCTG and CAGGTG motifs, respectively, and identified their preferred sequences at positions flanking these elements (Fig. 3D) (8) . It is remarkable that only a subset of the sequences selected here in vivo contained a CAGGTG motif and that relatively few (4 of 15) of the active plasmids contained the base preferred by MyoD at position Ϫ4 or ϩ4. However, the majority of the sequences selected by this method are identical or very similar to E boxes in the native promoters of the transcriptional regulators MyoD, myogenin, and MRF4, as well as in the promoters of many muscle structural protein genes. For instance, the hexamer core CAAGTG, which was not identified through in vitro binding selection but was recovered repeatedly by SITE, has been observed to date only in the MyoD promoter. Among them, sequence 5 resembles the MyoD distal regulatory region 1, which is important for transactivation of the MyoD promoter (69) , and sequence 15 is very similar to the E box in the MyoD proximal regulatory region, which is indispensable for both distal regulatory region transactivation (69) and autoregulation (80) by MyoD. Although the disproportionate representation of sequences 5 and 15 suggests that the arbitrarily chosen number of cells from which plasmids were recovered may have contained sequences of limited complexity, a variety of different sequences that indeed differ from the preferred in vitro consensus were selected.
Perhaps the most striking aspect of the selected MyoDresponsive sequences is that they closely resemble functional E boxes that are present in the promoters of muscle-specific genes ( Fig. 3B and C) 8) . This resemblance is apparent not only in their core hexamers but also in flanking sequences, many with identical pentamer half-sites (Fig. 3C) . In their natural promoter context, they are also capable of mediating transcriptional activation by the myogenic bHLH proteins, which apparently function as heterodimers with E proteins. These muscle-specific sites can, in general, be bound in vitro by MyoD and the other myogenic bHLH proteins and by heterodimers of these proteins with E proteins. The MyoD-responsive sequences selected here by SITE can similarly be bound by MyoD-E heterodimers (although the in vitro binding affinities do not parallel the in vivo transcriptional activity [data not shown]), and when we examined them in the cotransfection assay, we found that they mediate activation by a tethered MyoD-E47 dimer (52) to levels no higher than those characteristic of cotransfected MyoD (data not shown). The simplest interpretation of these findings is that these selected sites are direct targets of heterodimers of cellular E proteins with the cotransfected MyoD or with other myogenic bHLH proteins that may be activated by MyoD (see below).
The SITE data thus support the notion that DNA binding alone is not sufficient for a bound MyoD (or other myogenic bHLH protein)-E heterodimer to be transcriptionally active. To confirm that this SITE experiment did not somehow simply miss functional sequences that more closely resemble optimal MyoD and MyoD-E in vitro binding sites, we tested such sites (Fig. 3B) in the HCA cassette for transactivation by MyoD. In this assay, surprisingly, an optimal in vitro MyoD-E site was inactive, and the activity of a preferred MyoD homodimer site was very low (Fig. 3B) . On the other hand, SITE recovered some transcriptionally active plasmids bearing a sequence that was strongly selected against by in vitro methods, e.g., T at the Ϫ4 position of the E47 protein half-site (8, 67) . These data indicate that the E boxes that are most responsive to MyoD in vivo do not necessarily correspond to the in vitro binding preferences of MyoD or MyoD-E complexes.
Role of promoter context in MyoD transactivation through different E boxes. One possible explanation for differences in vivo and in vitro is that in vivo repressors might bind to certain E-box sequences and prevent MyoD from binding to these sites and activating transcription. Alternatively, differences among interacting proteins on these promoters might affect the conformation of the DNA and/or of the protein-DNA complex in a way that prevents particular E-box sequences from acting as an effective enhancer. To distinguish between these possibilities, we compared the abilities of different E boxes to activate transcription in the HCA promoter and the MCK enhancer/promoter. The 3,300-bp enhancer/promoter of MCK contains two E boxes that are targets of MyoD activation (37, 74) . A 115-bp segment including these E boxes that retains all of the muscle-specific activity of the enhancer (35) was used for the E-box substitution experiment (Fig. 4A) , the results of which are shown in Fig. 4B . The sequence 5 E-box decamer, a strong binding site in vitro and a strong activation site in the HCA promoter, was only moderately active when replacing the The sort gates for ␤-Gal activity were set such that the ratios of FITC fluorescence intensity of the gate over that of the bulk of ␤-Gal-negative cells were 150, 500, and 700 for the first, second, and third rounds, respectively. Note that the fluorescence intensity axis is logarithmic. Dead cells (propidium iodide bright) were eliminated through a second fluorescence gating. Cell debris, doublets, and larger clumps were gated out by forward-and side-scattering settings. The upper panels are histograms of the FITC intensities of all cells; the lower panels show the sorted cells while they were accumulating over an arbitrary period during the sorting. The cells containing FITC levels higher than the sort gate were collected, and the plasmid DNA was extracted and amplified in E. coli cells in order to do the next round of SITE. (B) Transcriptional activation by sequences selected from the third round of SITE. The plasmids recovered from the third round of the selection were transfected individually with the MyoD expression vector into 3T3 cells. ␤-Gal activity was measured from the cell lysates, using ONPG as the substrate. Each datum point was the average of at least three independent transfections. The data were plotted as the fold activation by MyoD over that of pEMSVscribe (MyoD Ϫ control vector). The Anecdote column lists known muscle-specific enhancer/promoters that contain E boxes with sequences identical or very similar to those selected by SITE. Only E boxes that were tested to be functional in the literature are listed. Note that in sequence 5, although the 3Ј flanking sequence CA can in theory be grouped with nucleotides immediately downstream to form another E box (CACCTG site), this second E box is nonfunctional (data not shown). mAchR-␥, mouse acetylcholine receptor ␥ subunit; DRR1, distal regulatory region 1; PRR, proximal regulatory region; sTnC, smooth muscle troponin C; MLC, myosin light chain; w.t., wild type; mut, mutant. (C) Alignment of selected E-box sequences to known enhancer/promoter sequences in muscle-specific genes. (Ϫ), the sequence displayed is antisense to the template strand. (D) Summary of in vitro DNA binding preferences of myogenic bHLH and E proteins. ‫,ء‬ data from reference 8; †, data from reference 24; ‡, data from reference 80. A line drawn over an uppercase letter indicates a base that is absent in that position, and a line over a lowercase letter indicates a decrease in use of that base.
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on March 1, 2013 by PENN STATE UNIV http://mcb.asm.org/ right (R) site of the MCK enhancer. Its activity was even lower if both left (L) and R sites were replaced. On the other hand, the in vitro optimal binding site (construct aa), although inactive in the HCA context, was the most active in the MCK context. It is interesting that the HCA E box, a poor binding site in vitro, acts as a strong activation site both in its native context and when replacing the L and R sites simultaneously in the MCK enhancer. Thus, these data for the MCK promoter confirmed the notion that the ability of an E-box enhancer to support transcriptional activation cannot be predicted from its affinity for the protein factors. These results demonstrate that promoter context is an important determinant of activation properties of different E-box sequences.
It is interesting that a majority (20 of 26) of the sites that were selected bear a MyoD half-site on the 5Ј end in proximity to the Sp1 site on the HCA promoter (Fig. 1B and 3B) . However, it is unlikely that Sp1 could be the determinant of context specificity because the MCK enhancer also contains an Sp1 site. Sp1 sites are also found adjacent to MyoD half-sites in the promoters of the acetylcholine receptor ␦ subunit (AchR-␦), myogenin, troponin, and MyoD genes, although the importance of these Sp1 sites has not been uniformly evaluated. Thus, it is not obvious why the activities of some E boxes are so different in the HCA and MCK promoters. Our results thus form a basis for further investigation of cis-acting elements that are involved in determining promoter context specificity.
Application of the SITE method. The SITE technique described here has, for the first time, used the power of randomsequence selection (6, 54, 64, 68) in metazoan cells to identify functional regulatory sites. It can yield sequences that are responsive to any transcription factor, or to a protein that activates such a factor, provided that either the cloned gene or a cell line expressing the factor is available. The reiterative selection process permits recovery of a large number of sites that mediate a range of transcriptional activities, with more stringent selection yielding more active sites. This method is likely to yield biologically significant sequences that might not be identified by in vitro methods, because they are selected in the presence of the full complement of cellular factors under physiological conditions and can thus provide rational guidance for designing reporter constructs. As such, the in vivo selection method provides an approach complementary to the in vitro method for discovering target sequences for regulatory proteins. A more important benefit of this strategy is that it allows a systematic comparison of the functional requirements of proteins under different circumstances and conditions and can thus illuminate critical regulatory mechanisms. For example, a comparison of the MyoD-responsive sequences identified in this study with the preferred in vitro binding sites of MyoD suggests the existence of particular sequence requirements for activation. The versatility of the SITE approach will now make it possible to undertake similar investigations of activation by MyoD (and its BR variants) in the context of other promoters and associated factors and to identify similarly sequences that respond to other bHLH proteins.
The SITE technique should be adaptable to a variety of other experimental situations. For example, repression sequences could be selected, provided that a screening step first identified cells that contain the reporter library DNA. It should be similarly possible to select native regulatory sequences from a library of genomic DNA fragments or, if transcribed positions were randomized, to identify sequences involved in RNA processing or translational control. If positions within coding sequences were randomized, a selection could identify the amino acid residues that are encoded by the corresponding positions which allow a transcription factor to function, as has been done in bacteria (34) and in Saccharomyces cerevisiae (56) . In principle, the number of positions that can be randomized in the SITE technique should be limited only by the number of cells that can be handled. For example, eight random positions will generate 4 8 (about 6.6 ϫ 10 4 ) different plasmid molecules. If one molecule were introduced per cell, screening of a library of this size would require on the order of 3 ϫ 10 5 cells (59), a number readily attainable by transient transfection. However, the efficiency of screening is actually higher, because each cell takes up multiple plasmids and because even at a high input copy number, positive cells can be identified by FACS, which can detect as few as 5 ␤-Gal enzyme molecules per cell (53) , is rapid (1/10 6 cells per h), and can be applied to different markers (e.g., the cell surface molecule CD4 [45] or green fluorescent protein [GFP] [11] ). Multiple markers can be used either alone or simultaneously to examine different sets of regulatory sequences. Alternatively, the technique can be applicable to other transient selection markers (e.g., puromycin resistance [71] ).
Specificity of MyoD-mediated transcriptional activation. Although the sequences identified here are responsive to MyoD, it is possible that these sequences actually are or include the direct targets of another myogenic bHLH protein. In cultured cells, expression of a myogenic bHLH protein can activate the corresponding endogenous gene along with other members of this group, with the particular myogenic genes activated varying among different lines (2, 33, 70) . In the 3T3 cells used in this study, MyoD generally does not activate the endogenous MyoD, myf-5, or MRF4 gene but can activate the myogenin gene. In the mouse, myf-5 and MyoD determine the myoblast cell fate (58), while myogenin is required to activate the full spectrum of sarcomeric genes (30, 50) , but in cells cultured from myogenin Ϫ/Ϫ mice, MyoD can also activate these genes (50) . Accordingly, we cannot determine whether in our experiments myogenin might have also contributed to the activation of sequences selected. However, it is unlikely that only myogenin (but not MyoD) is the direct activator, because when the selected sequences were cotransfected with a myogenin expression vector, they were activated to levels only half as high as those achieved by MyoD. As these sites are bound by MyoD-E heterodimers in vitro and activated similarly by MyoD and MyoD-E tethered dimers in vivo (data not shown), and since the DNA binding requirements of MyoD in vitro and those of myogenin with the nuclear extracts are virtually identical (Fig.  3D) (8, 79) , the most likely conclusion appears to be that the selected regulatory sites may be the direct targets of heterodimers of either MyoD or myogenin with endogenous cellular E proteins.
The group of sequences that were identified in this experiment share some attributes with, but are not identical to, the preferred in vitro binding sites for MyoD (or myogenin) or MyoD-E complexes. In the HCA promoter, these bHLH complexes might bind cooperatively with neighboring proteins, and these interactions might have contributed enough binding energy to have relaxed the sequence requirements for activation. However, two lines of evidence argue against this interpretation. First, an optimal site was not capable of supporting activation in this context (Fig. 3B) . Second, the selected sequences were actually less similar to the in vitro preferences than to E boxes found in the native promoters of muscle-specific genes. These native E boxes have been shown to be important for auto-and/or cross-activation of the myogenic bHLH genes or for activation of muscle structural genes by these bHLH proteins, suggesting that the sequences selected here by SITE are biologically significant.
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transcriptional activation by muscle-specific bHLH protein MyoD. The data indicate that only a subset of MyoD binding sites allow activation of transcription in the HCA promoter context and that certain E boxes function differently in different muscle-specific promoters. These findings demonstrate that promoter context plays an important role in transcriptional activation by MyoD through E boxes. Promoter context could affect transcriptional activation in several ways. For example, the neighboring protein factors could influence the conformation of the promoter DNA and/or of the protein-E box complex; different proteins could also recruit distinct associated factors to the promoters. In addition, our findings are reminiscent of the positive-control MyoD BR mutations (17, 76) , which also appear to permit DNA binding but not activation. Significantly, these same BR residues not only appear to influence the conformation of the protein-DNA complex (19, 44) but also have been implicated in interactions with proposed regulatory factors (9, 16, 17, 47, 76) . The findings described here indicate that some, or perhaps all, of the potential regulatory interactions require specific DNA sequences, which themselves could influence the conformation of the bound MyoD-E complex. It remains to be determined whether such conformational changes might provide distinctive targets for coactivators or repressors or would derive from such interactions.
